Enoxaparin Sodium Production Cost Reports

The report provides a detailed analysis essential for establishing an Enoxaparin Sodium manufacturing plant. It encompasses all critical aspects necessary for Enoxaparin Sodium production, including the cost of Enoxaparin Sodium production, Enoxaparin Sodium plant cost, Enoxaparin Sodium production costs, and the overall Enoxaparin Sodium manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Enoxaparin Sodium production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Enoxaparin Sodium is a low molecular weight heparin, utilized as an anticoagulant for the treatment and prevention of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to treat acute coronary syndrome (ACS). It is commonly used for VTE prophylaxis in surgical patients, mainly those who undergo hip or knee replacements. It can also be used during hemodialysis to prevent clotting. It also finds application as a bridging therapy for patients transitioning between anticoagulants. It is administered via subcutaneous injection and works by inhibiting blood-clotting proteins to reduce the risk of clot formation.

The market demand for Enoxaparin Sodium is majorly driven by its application as an anticoagulant for the treatment and prevention of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE), which elevates its demand in the medical and pharmaceutical industries. The global rise in the awareness about the treatment of various cardiovascular diseases supports the growth of the market. Its function to manage acute coronary syndrome (ACS) and VTE prophylaxis in surgical patients, also contributes to its market growth in the medical and pharmaceutical industries. The global rise in the cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) boosts the demand for effective anticoagulant therapies, such as Enoxaparin Sodium. Also, various innovations such as prefilled syringes and auto-injectors make administration easier and enhance patient compliance, which promotes industrial Enoxaparin Sodium procurement.

Raw Material for Enoxaparin Sodium Production

According to the Enoxaparin Sodium manufacturing plant project report, the various raw material for Enoxaparin Sodium production includes heparin sodium.

Manufacturing Process of Enoxaparin Sodium

The extensive Enoxaparin Sodium production cost report consists of the following major industrial manufacturing process:

• Production from heparin sodium: The manufacturing process of Enoxaparin sodium initiates with the extraction of heparin sodium from porcine intestinal mucosa via a multi-step process. The process starts with the conversion of heparin sodium into benzethonium heparinate, followed by the reaction with benzyl chloride to form crude heparin benzyl ester. This ester is precipitated using water and purified with sodium acetate to isolate the sodium salt. The next step involves alkaline depolymerization of the heparin benzyl ester sodium salt with sodium hydroxide to produce crude Enoxaparin Sodium. The compound undergoes purification via bleaching with hydrogen peroxide. The final step is reprecipitation to obtain the final product.

Properties of Enoxaparin Sodium

Enoxaparin Sodium is a clear liquid solution having a molecular formula (C26H40N2O36S5)n. It is a low molecular weight heparin (LMWH) commonly used as an anticoagulant. It has a pH in the range of 5.5 to 7.5. It is soluble in water. It has a log P value of -10.8, which indicates its high hydrophilicity. It is stable under normal conditions, but care should be taken to avoid exposure to extreme temperatures or conditions that could affect its efficacy. Its mechanism of action involves binding to antithrombin III, which leads to the inactivation of factor Xa and indirectly inhibits thrombin (factor IIa), which prevents clot formation.